Yazen raises €50M to scale digital obesity care across Europe

Yazen, the Lund-based digital health provider for medical weight management, has raised €50M in a round led by Verdane, with existing investor Evli Growth Partners participating, to expand across Europe and into broader cardiometabolic care (company announcement, 8 October 2026).

Obesity care is the most crowded corner of European digital health right now, and most of the GLP-1-era startups in it will not survive the decade. And yet the serious capital keeps arriving. This week it landed in Lund – and in size.

A €50M cheque from Verdane

The round, announced on 8 October, is €50M – around SEK 500M – led by the European growth investor Verdane, with Evli Growth Partners, the previous lead investor, coming back in (company announcement, 8 October 2026). It is the company’s largest raise to date, and in effect the Series B the founders had trailed at €30M in June 2026, landing well above that figure (Rapidus, June 2026, via Swedish Tech News) – even if the company’s own announcement skips the label.

It follows a €19.5M Series A in November 2024, co-led by Evli Growth Partners and Helsana HealthInvest (Startups Magazine, November 2024), and a €6.5M credit facility from HSBC Innovation Banking earlier in 2026 (Swedish Tech News, October 2026). The new money goes, in the company’s words, to scaling its evidence-based care model across Europe, entering more European markets and broadening treatment across cardiometabolic care.

“This funding provides the scale to reach more European markets,” said Mikael Hed, Yazen’s chairman and a growth partner at Evli Growth Partners, in the announcement.

Five years, eight markets, 115 doctors

Founded in Lund in 2021 by Fredrik Meurling, Magnus Nyhlén and Martin Carlsson, Yazen pairs weight-loss medication with continuous digital care from doctors, dietitians, psychologists and physiotherapists. The thesis is that the drugs are the easy part; keeping patients in structured care is the product.

The numbers behind the round: 290 employees, of whom 210 are clinical staff including 115 licensed doctors; more than 50,000 patients currently in treatment and over 70,000 treated in total, across Sweden, Norway, Denmark, the Netherlands, the UK, Germany, Switzerland and Spain (company announcement, 8 October 2026). At the Series A, Yazen counted just over 20,000 patients, in Sweden alone (Startups Magazine, November 2024). Revenue nearly doubled in 2025 to €29.4M (company figures reported by Swedish Tech News, October 2026).

The retention claim is the one that matters. A 2025 study of Yazen’s own patient base reports 70% of patients still in treatment after 12 months, against international figures the company cites of 20-50% stopping within a year (company announcement, 8 October 2026). These are the company’s numbers, not an independent trial – but retention is the metric this whole category lives or dies on. “Obesity is a chronic, progressive disease, not a character flaw,” said CEO Fredrik Meurling in the announcement.

A $71.6bn market compounding at 22% a year

So what is Verdane actually buying into? Globally, digital health for obesity was a $71.6bn market in 2025, projected to grow at a 22.18% CAGR from 2026 to 2035 (Towards Healthcare, April 2026). No equally credible Europe-only sizing exists yet for the digital segment – a gap worth noting in itself.

For scale against the rounds we track in our fundraising data: the two healthcare rounds we covered earlier this week – Vocca’s $20M Series A and Rivercell’s €22M seed – together are smaller than this single cheque. And a company that nearly doubles revenue in a market compounding at 22% is growing roughly four times faster than the tide beneath it.

Growth money is consolidating the GLP-1 wave

The pattern we are seeing: the GLP-1 wave spawned dozens of prescription-and-subscription channels across Europe, and growth investors are now picking the few with licensed clinical operations and retention data rather than funding another storefront. “Yazen stands out as a reliable and scalable leader in medical weight management,” said Verdane principal Cecilia Nytorp in the announcement – the operative words being reliable and scalable, not fastest or cheapest.

The good news for European health founders is that this is a category where our fragmented, regulated markets work as a moat rather than a tax. A provider that has built licensed clinical teams in eight countries, from Lund, in five years, has done the thing we keep saying European startups cannot do. What to watch next is the broadening into cardiometabolic care – from one disease to the cluster of conditions around it – and which of Europe’s remaining markets Yazen enters first.

The next test is not another round; it is whether patients stay a second year. Watch the retention curve, not the round count.